Compare WNC & ARMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WNC | ARMP |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.2M | 383.7M |
| IPO Year | 2009 | 1996 |
| Metric | WNC | ARMP |
|---|---|---|
| Price | $7.56 | $9.22 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $11.00 | ★ $15.00 |
| AVG Volume (30 Days) | ★ 633.6K | 64.6K |
| Earning Date | 05-01-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.84% | N/A |
| EPS Growth | ★ 179.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $2,027,489,000.00 | N/A |
| Revenue This Year | $10.65 | N/A |
| Revenue Next Year | $14.06 | N/A |
| P/E Ratio | $1.50 | ★ N/A |
| Revenue Growth | ★ 8.81 | N/A |
| 52 Week Low | $7.10 | $1.17 |
| 52 Week High | $12.94 | $14.98 |
| Indicator | WNC | ARMP |
|---|---|---|
| Relative Strength Index (RSI) | 34.55 | 40.04 |
| Support Level | N/A | $5.14 |
| Resistance Level | $9.48 | $12.11 |
| Average True Range (ATR) | 0.49 | 1.60 |
| MACD | -0.11 | -0.49 |
| Stochastic Oscillator | 19.57 | 0.00 |
Wabash National Corp operates as the innovation leader of connected solutions for the transportation, logistics, and distribution industries. The Company manages its business in two operating and reportable segments: Transportation Solutions and Parts & Services. It designs and manufactures products including dry freight and refrigerated trailers, platform trailers, tank trailers, dry and refrigerated truck bodies, structural composite panels and products, trailer aerodynamic solutions, and specialty food-grade processing equipment.
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.